Lifotronic(688389)2024-08-02 07:34Financial Performance - The company expects a significant improvement in gross margin for both the fiscal year 2023 and Q1 2024, primarily due to increased sales of in vitro diagnostic reagents and a higher proportion of self-produced raw materials [2] - The gross margin is projected to stabilize at a reasonable level, while the expense ratio will fluctuate based on the development of various product lines [3] Business Growth Expectations - The company anticipates high growth rates in its three main IVD business segments: chemiluminescence, glycosylated hemoglobin, and specific protein, with the latter showing unexpected growth in Q1 2024 [3] - The domestic chemiluminescence market share is substantial, indicating significant growth potential for the company's chemiluminescence business [3] Skin Aesthetic Business - The company officially entered the skin aesthetic market in 2023 and has received positive market feedback since launching its whitening product in November 2023 [4] - There is a large consumer market potential in the skin aesthetic sector, prompting the company to invest in personnel and resources to enhance its marketing capabilities [4] Regulatory Impact - Anti-corruption measures initiated in August 2023 have affected the speed of instrument installations in the luminescence industry, but the company maintains a positive outlook and compliance with regulations [4] Long-term Strategy - The company is focused on becoming a multi-market, multi-business platform, with four key business segments: IVD, clinical medicine, skin aesthetics, and consumer health, supporting its long-term growth [4]